EXCLUSIVE: NanoViricides Reports It Has Completed Its Oral Gummies And Lung Inhalation Formulations Development For Its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2